Quest Diagnostics Inc vs Domino's Pizza, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.77 (market cap $25.48B), while Domino's Pizza, Inc. trades at $307.42 (market cap $10.21B). The key difference: Quest Diagnostics Inc is far larger — about 2.5× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Domino's Pizza, Inc. for 106 Days on average.
| DGX | DPZ | |
|---|---|---|
Market Cap | $25.48B | $10.21B |
Volume | 941,866 | 916,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $438.42 |
52-Week Low | $173.49 | $282.89 |
Typical Hold Time | 56 Days | 106 Days |
Enterprise Value | $31.23B | $15.17B |
Dividend Yield | 1.49% | 2.58% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Domino's Pizza (DPZ) trades at $309.02, up 1.95% with a bullish technical signal despite recent earnings misses. The company maintains strong fundamentals with $4.94B revenue, 11.86% net margin, and positive cash flow trends. Recent news highlights dividend stability concerns amid high debt levels and store closures, while analyst consensus remains positive with a $373 price target representing 21% upside potential.
DPZ presents a value opportunity with reasonable valuation (P/E 17.5) but faces execution risks from consecutive earnings misses and substantial debt burden. The stock's 28% YTD decline creates potential for recovery if Q3 earnings beat expectations, though competitive pressures and franchisee challenges require monitoring for sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →